Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
Objectives We sought to compare outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with or without previous coronary artery bypass grafts (CABG). Background Limited information exists regarding procedural success and cl...
Gespeichert in:
Veröffentlicht in: | JACC. Cardiovascular interventions 2010-03, Vol.3 (3), p.343-351 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 351 |
---|---|
container_issue | 3 |
container_start_page | 343 |
container_title | JACC. Cardiovascular interventions |
container_volume | 3 |
creator | Welsh, Robert C., MD Granger, Christopher B., MD Westerhout, Cynthia M., PhD Blankenship, James C., MD Holmes, David R., MD O'Neill, William W., MD Hamm, Christian W., MD Van de Werf, Frans, MD, PhD Armstrong, Paul W., MD |
description | Objectives We sought to compare outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with or without previous coronary artery bypass grafts (CABG). Background Limited information exists regarding procedural success and clinical outcomes of STEMI patients with CABG undergoing primary PCI. Methods The APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial was a randomized, placebo-controlled trial of pexelizumab in STEMI patients with planned primary PCI: 128 of 5,745 (2.2%) patients had prior CABG. Clinical/procedural characteristics, culprit vessel (infarct-related artery [IRA]), and 90-day clinical outcomes were compared. Results Patients with previous CABG were more frequently men, older, had a higher incidence of comorbidities and multivessel disease. In patients with versus without prior CABG, PCI was performed less frequently, that is, 78.9% versus 93.9%; of those with prior CABG receiving PCI, Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 was also restored less often, that is, 82.5% versus 91.6% (both p < 0.001). In prior CABG, there was a nearly even designation of the IRA as a bypass graft (n = 63) versus a native vessel (n = 55): IRA post-PCI TIMI flow grade 3 was achieved in 66.7% versus 88.0%, respectively (p = 0.043). Prior CABG patients had increased 90-day death and composite 90-day death/congestive heart failure/shock. Excess death remained significant after multivariable adjustment (hazard ratio: 1.9, 95% confidence interval: 1.08 to 3.33, p = 0.025). When prior CABG patients were stratified by the type of IRA, there was further discrimination of the increased 90-day death, that is, 19% bypass graft (n = 63) versus 5.7% native vessel (n = 55, p = 0.05), respectively. Conclusions Prior CABG patients with STEMI are less likely to undergo acute reperfusion, have worse angiographic outcomes following primary PCI, and higher 90-day mortality. These findings are especially applicable when the IRA was a bypass graft. |
doi_str_mv | 10.1016/j.jcin.2009.12.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733350337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1936879810000257</els_id><sourcerecordid>733350337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-871c4b8fb278b77a2862db0cba3d3bb9aced9221ba0fe393a7711ac4bcda4c093</originalsourceid><addsrcrecordid>eNp9Uktv1DAQjhCIlsIf4IB845Tgx24cSwiprNqyUlFX2kUcLceZgEM2Xmxnpf0d_cNMSAGJQ30Za_w95uEse81owSgr33VFZ91QcEpVwXhBafUkO2eVLHNZ0uVTvCtR5pVU1Vn2IsaO0pIqyZ9nZ5xyVSlVnmf3m-B8ICsf_GDCiVyGBBg-ng4mRnITTJvIxiQHQ4rkq0vfyXaXb-HbHhPkqocjvvmBfD55a0LjTE_WQ2uC_Z3dBTAJmpmHRvvJYQPBjskM4Mf4z3c9oO8RRZH3MnvWmj7Cq4d4kX25vtqtPuW3dzfr1eVtbhfLRcLGmF3UVVtzWdVSGl6VvKmprY1oRF0rY6FRnLPa0BaEEkZKxgxSbGMWlipxkb2ddQ_B_xwhJr130ULfz8VpKYRYUiEkIvmMtMHHGKDVh7kbzaiedqE7Pe1CT7vQjGvcBZLePMiP9R6av5Q_w0fA-xkA2OTRQdDR4qCxbBfAJt1497j-h__otneDs6b_ASeInR_DgOPTTEck6O30G6bPwCgevpTiF56Ls7o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733350337</pqid></control><display><type>article</type><title>Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB Electronic Journals Library</source><creator>Welsh, Robert C., MD ; Granger, Christopher B., MD ; Westerhout, Cynthia M., PhD ; Blankenship, James C., MD ; Holmes, David R., MD ; O'Neill, William W., MD ; Hamm, Christian W., MD ; Van de Werf, Frans, MD, PhD ; Armstrong, Paul W., MD</creator><creatorcontrib>Welsh, Robert C., MD ; Granger, Christopher B., MD ; Westerhout, Cynthia M., PhD ; Blankenship, James C., MD ; Holmes, David R., MD ; O'Neill, William W., MD ; Hamm, Christian W., MD ; Van de Werf, Frans, MD, PhD ; Armstrong, Paul W., MD ; APEX AMI Investigators</creatorcontrib><description>Objectives We sought to compare outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with or without previous coronary artery bypass grafts (CABG). Background Limited information exists regarding procedural success and clinical outcomes of STEMI patients with CABG undergoing primary PCI. Methods The APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial was a randomized, placebo-controlled trial of pexelizumab in STEMI patients with planned primary PCI: 128 of 5,745 (2.2%) patients had prior CABG. Clinical/procedural characteristics, culprit vessel (infarct-related artery [IRA]), and 90-day clinical outcomes were compared. Results Patients with previous CABG were more frequently men, older, had a higher incidence of comorbidities and multivessel disease. In patients with versus without prior CABG, PCI was performed less frequently, that is, 78.9% versus 93.9%; of those with prior CABG receiving PCI, Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 was also restored less often, that is, 82.5% versus 91.6% (both p < 0.001). In prior CABG, there was a nearly even designation of the IRA as a bypass graft (n = 63) versus a native vessel (n = 55): IRA post-PCI TIMI flow grade 3 was achieved in 66.7% versus 88.0%, respectively (p = 0.043). Prior CABG patients had increased 90-day death and composite 90-day death/congestive heart failure/shock. Excess death remained significant after multivariable adjustment (hazard ratio: 1.9, 95% confidence interval: 1.08 to 3.33, p = 0.025). When prior CABG patients were stratified by the type of IRA, there was further discrimination of the increased 90-day death, that is, 19% bypass graft (n = 63) versus 5.7% native vessel (n = 55, p = 0.05), respectively. Conclusions Prior CABG patients with STEMI are less likely to undergo acute reperfusion, have worse angiographic outcomes following primary PCI, and higher 90-day mortality. These findings are especially applicable when the IRA was a bypass graft.</description><identifier>ISSN: 1936-8798</identifier><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2009.12.008</identifier><identifier>PMID: 20298996</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Angioplasty, Balloon, Coronary - adverse effects ; Angioplasty, Balloon, Coronary - mortality ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Cardiovascular ; Coronary Angiography ; Coronary Artery Bypass - adverse effects ; Coronary Artery Bypass - mortality ; coronary artery bypass graft ; Female ; Graft Occlusion, Vascular - diagnostic imaging ; Graft Occlusion, Vascular - drug therapy ; Graft Occlusion, Vascular - etiology ; Graft Occlusion, Vascular - mortality ; Graft Occlusion, Vascular - therapy ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myocardial Infarction - diagnostic imaging ; Myocardial Infarction - drug therapy ; Myocardial Infarction - etiology ; Myocardial Infarction - mortality ; Myocardial Infarction - therapy ; percutaneous coronary intervention ; Proportional Hazards Models ; Risk Assessment ; Risk Factors ; Single-Chain Antibodies - therapeutic use ; ST-segment elevation myocardial infarction ; Time Factors ; Treatment Outcome</subject><ispartof>JACC. Cardiovascular interventions, 2010-03, Vol.3 (3), p.343-351</ispartof><rights>American College of Cardiology Foundation</rights><rights>2010 American College of Cardiology Foundation</rights><rights>Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-871c4b8fb278b77a2862db0cba3d3bb9aced9221ba0fe393a7711ac4bcda4c093</citedby><cites>FETCH-LOGICAL-c454t-871c4b8fb278b77a2862db0cba3d3bb9aced9221ba0fe393a7711ac4bcda4c093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcin.2009.12.008$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20298996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Welsh, Robert C., MD</creatorcontrib><creatorcontrib>Granger, Christopher B., MD</creatorcontrib><creatorcontrib>Westerhout, Cynthia M., PhD</creatorcontrib><creatorcontrib>Blankenship, James C., MD</creatorcontrib><creatorcontrib>Holmes, David R., MD</creatorcontrib><creatorcontrib>O'Neill, William W., MD</creatorcontrib><creatorcontrib>Hamm, Christian W., MD</creatorcontrib><creatorcontrib>Van de Werf, Frans, MD, PhD</creatorcontrib><creatorcontrib>Armstrong, Paul W., MD</creatorcontrib><creatorcontrib>APEX AMI Investigators</creatorcontrib><title>Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>Objectives We sought to compare outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with or without previous coronary artery bypass grafts (CABG). Background Limited information exists regarding procedural success and clinical outcomes of STEMI patients with CABG undergoing primary PCI. Methods The APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial was a randomized, placebo-controlled trial of pexelizumab in STEMI patients with planned primary PCI: 128 of 5,745 (2.2%) patients had prior CABG. Clinical/procedural characteristics, culprit vessel (infarct-related artery [IRA]), and 90-day clinical outcomes were compared. Results Patients with previous CABG were more frequently men, older, had a higher incidence of comorbidities and multivessel disease. In patients with versus without prior CABG, PCI was performed less frequently, that is, 78.9% versus 93.9%; of those with prior CABG receiving PCI, Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 was also restored less often, that is, 82.5% versus 91.6% (both p < 0.001). In prior CABG, there was a nearly even designation of the IRA as a bypass graft (n = 63) versus a native vessel (n = 55): IRA post-PCI TIMI flow grade 3 was achieved in 66.7% versus 88.0%, respectively (p = 0.043). Prior CABG patients had increased 90-day death and composite 90-day death/congestive heart failure/shock. Excess death remained significant after multivariable adjustment (hazard ratio: 1.9, 95% confidence interval: 1.08 to 3.33, p = 0.025). When prior CABG patients were stratified by the type of IRA, there was further discrimination of the increased 90-day death, that is, 19% bypass graft (n = 63) versus 5.7% native vessel (n = 55, p = 0.05), respectively. Conclusions Prior CABG patients with STEMI are less likely to undergo acute reperfusion, have worse angiographic outcomes following primary PCI, and higher 90-day mortality. These findings are especially applicable when the IRA was a bypass graft.</description><subject>Aged</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>Angioplasty, Balloon, Coronary - mortality</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Cardiovascular</subject><subject>Coronary Angiography</subject><subject>Coronary Artery Bypass - adverse effects</subject><subject>Coronary Artery Bypass - mortality</subject><subject>coronary artery bypass graft</subject><subject>Female</subject><subject>Graft Occlusion, Vascular - diagnostic imaging</subject><subject>Graft Occlusion, Vascular - drug therapy</subject><subject>Graft Occlusion, Vascular - etiology</subject><subject>Graft Occlusion, Vascular - mortality</subject><subject>Graft Occlusion, Vascular - therapy</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - diagnostic imaging</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - therapy</subject><subject>percutaneous coronary intervention</subject><subject>Proportional Hazards Models</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Single-Chain Antibodies - therapeutic use</subject><subject>ST-segment elevation myocardial infarction</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1936-8798</issn><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uktv1DAQjhCIlsIf4IB845Tgx24cSwiprNqyUlFX2kUcLceZgEM2Xmxnpf0d_cNMSAGJQ30Za_w95uEse81owSgr33VFZ91QcEpVwXhBafUkO2eVLHNZ0uVTvCtR5pVU1Vn2IsaO0pIqyZ9nZ5xyVSlVnmf3m-B8ICsf_GDCiVyGBBg-ng4mRnITTJvIxiQHQ4rkq0vfyXaXb-HbHhPkqocjvvmBfD55a0LjTE_WQ2uC_Z3dBTAJmpmHRvvJYQPBjskM4Mf4z3c9oO8RRZH3MnvWmj7Cq4d4kX25vtqtPuW3dzfr1eVtbhfLRcLGmF3UVVtzWdVSGl6VvKmprY1oRF0rY6FRnLPa0BaEEkZKxgxSbGMWlipxkb2ddQ_B_xwhJr130ULfz8VpKYRYUiEkIvmMtMHHGKDVh7kbzaiedqE7Pe1CT7vQjGvcBZLePMiP9R6av5Q_w0fA-xkA2OTRQdDR4qCxbBfAJt1497j-h__otneDs6b_ASeInR_DgOPTTEck6O30G6bPwCgevpTiF56Ls7o</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Welsh, Robert C., MD</creator><creator>Granger, Christopher B., MD</creator><creator>Westerhout, Cynthia M., PhD</creator><creator>Blankenship, James C., MD</creator><creator>Holmes, David R., MD</creator><creator>O'Neill, William W., MD</creator><creator>Hamm, Christian W., MD</creator><creator>Van de Werf, Frans, MD, PhD</creator><creator>Armstrong, Paul W., MD</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention</title><author>Welsh, Robert C., MD ; Granger, Christopher B., MD ; Westerhout, Cynthia M., PhD ; Blankenship, James C., MD ; Holmes, David R., MD ; O'Neill, William W., MD ; Hamm, Christian W., MD ; Van de Werf, Frans, MD, PhD ; Armstrong, Paul W., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-871c4b8fb278b77a2862db0cba3d3bb9aced9221ba0fe393a7711ac4bcda4c093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>Angioplasty, Balloon, Coronary - mortality</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Cardiovascular</topic><topic>Coronary Angiography</topic><topic>Coronary Artery Bypass - adverse effects</topic><topic>Coronary Artery Bypass - mortality</topic><topic>coronary artery bypass graft</topic><topic>Female</topic><topic>Graft Occlusion, Vascular - diagnostic imaging</topic><topic>Graft Occlusion, Vascular - drug therapy</topic><topic>Graft Occlusion, Vascular - etiology</topic><topic>Graft Occlusion, Vascular - mortality</topic><topic>Graft Occlusion, Vascular - therapy</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - diagnostic imaging</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - therapy</topic><topic>percutaneous coronary intervention</topic><topic>Proportional Hazards Models</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Single-Chain Antibodies - therapeutic use</topic><topic>ST-segment elevation myocardial infarction</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Welsh, Robert C., MD</creatorcontrib><creatorcontrib>Granger, Christopher B., MD</creatorcontrib><creatorcontrib>Westerhout, Cynthia M., PhD</creatorcontrib><creatorcontrib>Blankenship, James C., MD</creatorcontrib><creatorcontrib>Holmes, David R., MD</creatorcontrib><creatorcontrib>O'Neill, William W., MD</creatorcontrib><creatorcontrib>Hamm, Christian W., MD</creatorcontrib><creatorcontrib>Van de Werf, Frans, MD, PhD</creatorcontrib><creatorcontrib>Armstrong, Paul W., MD</creatorcontrib><creatorcontrib>APEX AMI Investigators</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Welsh, Robert C., MD</au><au>Granger, Christopher B., MD</au><au>Westerhout, Cynthia M., PhD</au><au>Blankenship, James C., MD</au><au>Holmes, David R., MD</au><au>O'Neill, William W., MD</au><au>Hamm, Christian W., MD</au><au>Van de Werf, Frans, MD, PhD</au><au>Armstrong, Paul W., MD</au><aucorp>APEX AMI Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>3</volume><issue>3</issue><spage>343</spage><epage>351</epage><pages>343-351</pages><issn>1936-8798</issn><eissn>1876-7605</eissn><abstract>Objectives We sought to compare outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with or without previous coronary artery bypass grafts (CABG). Background Limited information exists regarding procedural success and clinical outcomes of STEMI patients with CABG undergoing primary PCI. Methods The APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial was a randomized, placebo-controlled trial of pexelizumab in STEMI patients with planned primary PCI: 128 of 5,745 (2.2%) patients had prior CABG. Clinical/procedural characteristics, culprit vessel (infarct-related artery [IRA]), and 90-day clinical outcomes were compared. Results Patients with previous CABG were more frequently men, older, had a higher incidence of comorbidities and multivessel disease. In patients with versus without prior CABG, PCI was performed less frequently, that is, 78.9% versus 93.9%; of those with prior CABG receiving PCI, Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 was also restored less often, that is, 82.5% versus 91.6% (both p < 0.001). In prior CABG, there was a nearly even designation of the IRA as a bypass graft (n = 63) versus a native vessel (n = 55): IRA post-PCI TIMI flow grade 3 was achieved in 66.7% versus 88.0%, respectively (p = 0.043). Prior CABG patients had increased 90-day death and composite 90-day death/congestive heart failure/shock. Excess death remained significant after multivariable adjustment (hazard ratio: 1.9, 95% confidence interval: 1.08 to 3.33, p = 0.025). When prior CABG patients were stratified by the type of IRA, there was further discrimination of the increased 90-day death, that is, 19% bypass graft (n = 63) versus 5.7% native vessel (n = 55, p = 0.05), respectively. Conclusions Prior CABG patients with STEMI are less likely to undergo acute reperfusion, have worse angiographic outcomes following primary PCI, and higher 90-day mortality. These findings are especially applicable when the IRA was a bypass graft.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20298996</pmid><doi>10.1016/j.jcin.2009.12.008</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1936-8798 |
ispartof | JACC. Cardiovascular interventions, 2010-03, Vol.3 (3), p.343-351 |
issn | 1936-8798 1876-7605 |
language | eng |
recordid | cdi_proquest_miscellaneous_733350337 |
source | MEDLINE; Elsevier ScienceDirect Journals; EZB Electronic Journals Library |
subjects | Aged Angioplasty, Balloon, Coronary - adverse effects Angioplasty, Balloon, Coronary - mortality Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Cardiovascular Coronary Angiography Coronary Artery Bypass - adverse effects Coronary Artery Bypass - mortality coronary artery bypass graft Female Graft Occlusion, Vascular - diagnostic imaging Graft Occlusion, Vascular - drug therapy Graft Occlusion, Vascular - etiology Graft Occlusion, Vascular - mortality Graft Occlusion, Vascular - therapy Humans Kaplan-Meier Estimate Male Middle Aged Myocardial Infarction - diagnostic imaging Myocardial Infarction - drug therapy Myocardial Infarction - etiology Myocardial Infarction - mortality Myocardial Infarction - therapy percutaneous coronary intervention Proportional Hazards Models Risk Assessment Risk Factors Single-Chain Antibodies - therapeutic use ST-segment elevation myocardial infarction Time Factors Treatment Outcome |
title | Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A15%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prior%20Coronary%20Artery%20Bypass%20Graft%20Patients%20With%20ST-Segment%20Elevation%20Myocardial%20Infarction%20Treated%20With%20Primary%20Percutaneous%20Coronary%20Intervention&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Welsh,%20Robert%20C.,%20MD&rft.aucorp=APEX%20AMI%20Investigators&rft.date=2010-03-01&rft.volume=3&rft.issue=3&rft.spage=343&rft.epage=351&rft.pages=343-351&rft.issn=1936-8798&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2009.12.008&rft_dat=%3Cproquest_cross%3E733350337%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733350337&rft_id=info:pmid/20298996&rft_els_id=1_s2_0_S1936879810000257&rfr_iscdi=true |